MENU
SEP 12 - 13 2023

The Future of Cutting-Edge Genomic Technologies for Liquid Biopsy Cancer Research​

Liquid biopsy is an emerging area of clinical research, particularly in the context of cancer. As a minimally invasive complementary or alternative approach to tissue biopsies, liquid biopsies are less risky, painful, and costly, and are increasingly being used to analyze biomarkers in liquid samples, such as blood. Recent advances in genomic technologies, such as digital PCR (dPCR) and next-generation sequencing (NGS), have enabled researchers to more comprehensively detect and study cancer-related mutations, even when they are very rare.  

With this panel of key opinion leaders in the liquid biopsy space, we dive deeper into the impact of genomics and genomics technologies on the current and future of  liquid biopsy clinical research and cancer management. At Thermo Fisher Scientific we are committed to developing robust sample preparation solutions for cell-free nucleic acids and highly sensitive liquid biopsy assays utilizing both dPCR and targeted NGS to enable cancer driver identification, serial monitoring, and potential recurrence detection. 


Speakers
  • Dr. Cristina Bilbao

    Senior Researcher in Molecular Biology, working in Hematology Service, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria
    BIOGRAPHY
  • Dr. Paul Hung

    Senior Director and General Manager of Digital PCR, Thermo Fisher Scientific
    BIOGRAPHY
  • Dr. K.J. Kao

    Head of the Department of Molecular Medicine and Research, Koo Foundation Sun Yat-Sen Cancer Center
    BIOGRAPHY
  • Dr. Cloud Paweletz

    Head of Research at the Belfer Center for Applied Cancer Science, Dana Faber Cancer Institute (DFCI)
    BIOGRAPHY
  • Dr. Luca Quagliata

    Vice President and Global Head of Medical Affairs for the Clinical Sequencing Oncology Division, Thermo Fisher Scientific
    BIOGRAPHY
  • Dr. Eloisa Jantus Lewintre, PhD

    Head of Molecular Oncology Laboratory, General University Hospital Research Foundation
  • Dr. Gorka Alkorta-Aranburu

    Codirector, Genetics of solid and hereditary tumors, University of Navarra
  • Matteo Allegretti, PhD

    Translational Oncology Research Unit, RCSS Regina Elena National Cancer Institute
    BIOGRAPHY

Agenda

  • SEP 13, 2023 10:00 AM PDT

    Webinar Series Part 2: The Future of Cutting-Edge Genomic Technologies for Liquid Biopsy Cancer Research

    Sponsored By: Thermo Fisher Scientific
    Dr. Eloisa Jantus Lewintre, PhD
    Head of Molecular Oncology Laboratory, General Universi...
    Dr. Gorka Alkorta-Aranburu
    Codirector, Genetics of solid and hereditary tumors, Un...
    Matteo Allegretti, PhD
    Translational Oncology Research Unit, RCSS Regina Elena...
  • September 13 at 9:30am IST, 12:00pm CST/SGT

    Webinar Series Part 2: The Future of Cutting-Edge Genomic Technologies for Liquid Biopsy Cancer Research

    Sponsored By: Thermo Fisher Scientific
    Dr. Eloisa Jantus Lewintre, PhD
    Head of Molecular Oncology Laboratory, General Universi...
    Dr. Gorka Alkorta-Aranburu
    Codirector, Genetics of solid and hereditary tumors, Un...
    Matteo Allegretti, PhD
    Translational Oncology Research Unit, RCSS Regina Elena...
  • September 13 at 10:00am CEST, 9:00am BST

    Webinar Series Part 2: The Future of Cutting-Edge Genomic Technologies for Liquid Biopsy Cancer Research

    Sponsored By: Thermo Fisher Scientific
    Dr. Eloisa Jantus Lewintre, PhD
    Head of Molecular Oncology Laboratory, General Universi...
    Dr. Gorka Alkorta-Aranburu
    Codirector, Genetics of solid and hereditary tumors, Un...
    Matteo Allegretti, PhD
    Translational Oncology Research Unit, RCSS Regina Elena...

Speakers

Liquid biopsy is an emerging area of clinical research, particularly in the context of cancer. As a minimally invasive complementary or alternative approach to tissue biopsies, liquid biopsies are less risky, painful, and costly, and are increasingly being used to analyze biomarkers in liquid samples, such as blood. Recent advances in genomic technologies such as digital PCR (dPCR) and next generation sequencing (NGS) have enabled researchers to more comprehensively detect and study cancer related mutations, even when they are very rare.  

In this panel of key opinion leaders in the liquid biopsy space, we dive deeper into the  the impact of genomics and genomics technologies on the current and future of liquid biopsy clinical research and cancer management.  

At Thermo Fisher Scientific we are committed to developing robust sample preparation solutions for cell-free nucleic acids and highly sensitive liquid biopsy assays utilizing both digital PCR (dPCR) and targeted next-generation sequencing (NGS) to enable cancer driver identification, serial monitoring, and recurrence detection. 


  • Dr. Cristina Bilbao

    Dr. Cristina Bilbao

    Senior Researcher in Molecular Biology, working in Hematology Service, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria

    BIOGRAPHY
  • Dr. Paul Hung

    Dr. Paul Hung

    Senior Director and General Manager of Digital PCR, Thermo Fisher Scientific

    BIOGRAPHY
  • Dr. K.J. Kao

    Dr. K.J. Kao

    Head of the Department of Molecular Medicine and Research, Koo Foundation Sun Yat-Sen Cancer Center

    BIOGRAPHY
  • Dr. Cloud Paweletz

    Dr. Cloud Paweletz

    Head of Research at the Belfer Center for Applied Cancer Science, Dana Faber Cancer Institute (DFCI)

    BIOGRAPHY
  • Dr. Luca Quagliata

    Dr. Luca Quagliata

    Vice President and Global Head of Medical Affairs for the Clinical Sequencing Oncology Division, Thermo Fisher Scientific

    BIOGRAPHY
  • Dr. Eloisa Jantus Lewintre, PhD

    Dr. Eloisa Jantus Lewintre, PhD

    Head of Molecular Oncology Laboratory, General University Hospital Research Foundation

  • Dr. Gorka Alkorta-Aranburu

    Dr. Gorka Alkorta-Aranburu

    Codirector, Genetics of solid and hereditary tumors, University of Navarra

  • Matteo Allegretti, PhD

    Matteo Allegretti, PhD

    Translational Oncology Research Unit, RCSS Regina Elena National Cancer Institute

    BIOGRAPHY
Help